Company Overview
Eir Pharmaceuticals, LLC is a biotechnology company based in Kansas City, operating primarily in development-stage and focusing on the creation and commercialization of health, wellness, and pharmaceutical products. The company exploits a proprietary biotechnology platform that spans several markets, including animal health, human consumer health, and human health. Eir Pharmaceuticals manages the manufacturing of drugs across multiple therapeutic areas with an emphasis on research and development (R&D). They maintain an Investigational Medicinal Products (IMP) license and a Manufacturing License which covers highly potent products such as oncology, cytotoxic, steroidal, and immunosuppressant molecules.
In a notable business development, Eir Pharmaceuticals was acquired by OPKO Health, Inc. in May 2015. OPKO Health is a publicly traded healthcare firm based in Miami, focusing on fields such as neurological disorders, infectious diseases, and oncology, as well as acquiring complementary pharmaceutical compounds and technologies.
Leadership Team
Dr. Andrew Skaff
- Position: Chief Executive Officer / Board Manager
- Educational Background: PhD in Biochemistry
- Professional Experience: Co-founder of Eir Pharmaceuticals in 2018 with over 20 years of experience in metabolic proteins and drug discovery, guiding the strategic vision and operations of the company.
Dr. Bill Duncan
- Position: Chairman, Board of Managers
- Educational Background: PhD in Organic Chemistry
- Professional Experience: Over 40 years in animal and human health, significantly contributing to strategic management and innovative directions.
Julie Sailors
- Position: Board Manager
- Educational Background: BS in Systematics & Ecology
- Professional Experience: More than 20 years in management and financial spheres, providing governance on financial strategies and organizational growth.
Dr. Gerald Wyckoff
- Position: Board Manager
- Educational Background: PhD in Genetics
- Professional Role: Chair, Division of Pharmacology and Pharmaceutical Sciences at UMKC, fostering research and development collaborations.
Product Pipeline
Eir Pharmaceuticals is engaged in the development of a diverse range of products aimed at enhancing both human and animal health:
- Animal Health: Includes pet food and treats, grooming products, and topical creams.
- Human Health: Focuses on anti-cancer treatments, wellness beverages, and topical creams.
- Consumer Goods: Offers products such as cosmetics and styling gels for overall well-being.
Financial Information and Activities
The company reported a seed funding of $70,000 in August 2019. It employs 178 professionals and generates an estimated annual revenue of approximately $35.8 million, despite a noted -1% decline in employee growth over the past year. The revenue per employee is estimated at $201,000.
Strategic Investments and Partnerships
Eir Pharmaceuticals holds a strategic investment position in companies like Gifthealth, which indicates a deliberate move to integrate software solutions for streamlined healthcare processes.
Competitors
Eir Pharmaceuticals operates in a competitive landscape with peers like AMBOSS, Osmosis, and HealthStream, which offer similar high-value services that could potentially challenge market share.
Industry Recognition and Licenses
The company's manufacturing facilities are approved by leading regulatory entities such as the EMA, FDA, and PMDA, ensuring high standards for quality and compliance in development and manufacturing procedures.
For further inquiries or details on Eir Pharmaceuticals' projects and initiatives, contact Dr. Andrew Skaff at skaff@eirpharmaceuticals.com.
Eir Pharmaceuticals' Headquarters:
10900 S Clay Blair Blvd STE 1600,
Olathe, KS 66061
